How India Exports Indomethacin to the World

Indomethacin, a nonsteroidal anti-inflammatory drug (NSAID), has been approved in the United States through multiple Abbreviated New Drug Applications (ANDAs). According to the FDA's Orange Book, numerous generic versions of indomethacin are available, indicating a well-established market presence. The most recent ANDA approval for indomethacin was granted in March 2025, reflecting ongoing interest and competition in the generic NSAID market.

The United States is the primary destination for indomethacin exports from India, accounting for 68.0% of the total export value. This significant market share underscores the importance of compliance with FDA regulations for Indian exporters. To date, there have been no import alerts issued by the FDA specifically for indomethacin, suggesting that Indian manufacturers have maintained compliance with U.S. regulatory standards. The regulatory pathway for indomethacin involves the submission of an ANDA, demonstrating bioequivalence to the reference listed drug, and adherence to current Good Manufacturing Practices (cGMP) as mandated by the FDA.

In the European Union, indomethacin is subject to marketing authorization by the European Medicines Agency (EMA). The EMA requires comprehensive data on quality, safety, and efficacy for approval. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval process. Both agencies mandate compliance with EU Good Manufacturing Practice (GMP) guidelines to ensure product quality and patient safety.

Indomethacin is included in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025. This inclusion highlights its recognized importance in treating priority health conditions globally. The drug is also listed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality specifications across different regions.

In India, indomethacin is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for indomethacin, allowing market-driven pricing. For export purposes, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national export regulations.

The primary patents for indomethacin have expired, leading to a competitive generic market. This expiration has facilitated the entry of multiple generic manufacturers, contributing to the drug's widespread availability and affordability.

In June 2025, the NPPA announced a revision of the ceiling prices for several essential medicines; however, indomethacin was not included in this list, allowing its pricing to remain market-driven.

In August 2025, the EMA issued updated guidelines on the manufacturing of NSAIDs, emphasizing stricter controls on impurities. Indian exporters targeting the EU market must ensure compliance with these enhanced standards to maintain market access.

In October 2025, the WHO released the 24th edition of the Model List of Essential Medicines, reaffirming indomethacin's status as an essential medicine. This inclusion underscores its continued relevance in global healthcare.

In December 2025, the FDA updated its guidance on bioequivalence studies for generic NSAIDs, including indomethacin. Manufacturers are advised to align their study designs with these new recommendations to facilitate ANDA approvals.

In February 2026, the CDSCO implemented a new online portal for the submission of export NOCs, streamlining the process for Indian pharmaceutical companies exporting drugs like indomethacin.

Indomethacin, a nonsteroidal anti-inflammatory drug (NSAID), is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where approximately 41% of KSMs used in U.S.-approved APIs are solely sourced from China, and 16% from India, as reported by the U.S. Pharmacopeia in October 2025.

Recent disruptions have highlighted the vulnerabilities in this supply chain. In February 2025, the FDA issued warning letters to API manufacturers in China and India for significant deviations from current Good Manufacturing Practices (cGMP), underscoring ongoing quality concerns. Such regulatory actions can lead to production halts, affecting the availability of essential drugs like Indomethacin.

Our proprietary trade data from 2022 to 2026 indicates that the top five Indian exporters account for 76.5% of Indomethacin exports, with HETERO LABS LIMITED alone contributing 41.6%. This high supplier concentration poses a significant risk; any operational or regulatory issues affecting these key players could disrupt the global supply chain.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at boosting domestic API production and reducing reliance on imports. As of November 2025, the sixth application round under the PLI scheme was launched, targeting priority APIs to enhance self-sufficiency. While this initiative is a positive step, its impact on reducing supplier concentration in the Indomethacin market remains to be seen.

Geopolitical tensions and shipping disruptions have further complicated the Indomethacin supply chain. Incidents in critical maritime routes, such as the Red Sea and the Strait of Hormuz, have led to delays and increased shipping costs. Additionally, escalating U.S.-China trade tensions have resulted in tariffs and export restrictions, affecting the availability and pricing of KSMs essential for Indomethacin production.

Regulatory bodies have responded to these challenges. In October 2025, the U.S. Pharmacopeia highlighted the risks associated with concentrated KSM sourcing, emphasizing the need for diversified supply chains to ensure drug availability. Such insights underscore the importance of addressing geopolitical and logistical vulnerabilities in pharmaceutical supply chains.

• Diversify Supplier Base: Engage with multiple API and KSM suppliers across different regions to reduce dependency on a single source.

• Enhance Domestic Production: Leverage government incentives like the PLI scheme to invest in local manufacturing capabilities for APIs and KSMs.

• Strengthen Quality Assurance: Implement robust quality control measures to comply with international cGMP standards, minimizing the risk of regulatory actions.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events and assess their potential impact on the supply chain.

• Develop Contingency Plans: Create comprehensive risk management strategies, including alternative shipping routes and emergency stockpiles, to address potential disruptions.

RISK_LEVEL: MEDIUM